AI-Powered Imaging Diagnostics Market Size to Reach USD 9.73 Billion by 2033 as Radiology AI, Software-Centric Platforms, and Modality-Specific Clinical Automation Accelerate Adoption

April 19, 2026 - The global AI-powered imaging diagnostics market reached USD 1.61 billion in 2024 and is expected to reach USD 9.73 billion by 2033, growing at a CAGR of 22.3% during 2025-2033, based on the market data provided. The market is expanding rapidly as healthcare systems use AI to improve image interpretation, prioritize urgent cases, reduce reporting delays, and support more consistent diagnostic workflows across radiology, cardiology, oncology, neurology, and other specialties. Public market trackers for adjacent AI-in-medical-imaging categories also show a similar scale and growth pattern, reinforcing the strength of current market momentum.

Request Exclusive Report Report: https://www.datamintelligence.com/download-sample/ai-powered-imaging-diagnostics-market

Growth is increasingly being led by software-driven deployments, modality-specific AI tools for CT, X-ray, MRI, ultrasound, mammography, and PET, and broader adoption by hospitals, specialty clinics, and diagnostic centers. Recent official updates from Philips, Qure.ai, and Rad AI show that the market is moving beyond stand-alone algorithms toward embedded workflow platforms, predictive imaging, advanced reporting, and larger clinical clearance footprints.

Recent Developments

Recent developments show that the competitive landscape is shifting toward deeper workflow integration, broader regulatory clearance, and more autonomous imaging support. On March 17, 2026, Philips said it is working with NVIDIA on predictive MRI image previews to support scan planning and more autonomous imaging workflows, using accelerated computing and domain-specific foundation models.

On February 25, 2026, Qure.ai announced that the FDA cleared qXR-Detect, adding six new indications and bringing the company's total to 26 FDA-cleared indications across 9 products. Qure.ai said chest radiography remains the most-performed imaging exam in the U.S., with about 70 million exams annually, making this expansion commercially important.

On December 1, 2025, Rad AI launched its next-generation speech recognition technology for radiology reporting, positioning it as a workflow-efficiency tool built on multi-model AI and advanced language understanding. The release reflects how imaging AI is moving beyond detection and into report creation and productivity support.

Philips also unveiled Rembra CT at ECR 2026 in March 2026, positioning it as a new high-speed CT platform designed for acute and high-demand imaging environments, reinforcing the trend toward AI-enabled imaging systems that combine hardware and software value.

Segment Analysis
By Component: Software

Software is the largest component segment in the market because most commercial value in AI-powered imaging diagnostics is being created through image analysis algorithms, workflow orchestration, triage tools, reporting automation, and cloud-connected decision support rather than through hardware alone. A recent public market summary for the adjacent AI medical imaging market says the software segment held about 55% share in 2024. Applying that share directionally to your 2024 market size of USD 1.61 billion implies an estimated software segment value of about USD 885.5 million. I'm treating that figure as a directional estimate because the share comes from a closely adjacent market definition rather than this exact dataset.

By Application: Radiology

Radiology remains the leading application segment because it handles the largest imaging volumes and is the earliest, deepest adoption zone for AI-assisted interpretation, triage, and reporting. A recent public market summary says radiology accounted for about 45% of the AI medical imaging market in 2024. Using that as a directional benchmark against your 2024 global market value of USD 1.61 billion suggests an estimated radiology segment size of about USD 724.5 million. That aligns with the large installed base of imaging studies and the growing number of radiology-focused FDA-cleared AI tools in the market.

Market Segmentation

The AI-powered imaging diagnostics market is segmented by Component into Software, Hardware, and Services. By Imaging Modality, the market includes Computed Tomography (CT), X-Ray Imaging, Magnetic Resonance Imaging (MRI), Ultrasound Imaging, Mammography, Positron Emission Tomography (PET), and Others. By Application, it covers Radiology, Cardiology, Ophthalmology, Oncology, Neurology, Orthopedic, Dentistry, and Others. By End-User, the market includes Hospitals, Specialty Clinics, Diagnostic Centers, Research & Academic Institutes, and Others. Key companies cited include deepc GmbH, Qure.ai Technologies Private Limited, DeepTek.ai, Koninklijke Philips N.V., Tempus AI, Inc., Rayscape, Infervision, AIKENIST, Rad AI, and Brainomix Limited.

Regional Analysis
United States

The United States remains the most commercially important national market for AI-powered imaging diagnostics because of its large imaging volumes, strong radiology IT base, high FDA activity, and faster integration of AI into hospital workflows. A current public market outlook for the adjacent U.S. AI in medical imaging market values the market at USD 524 million in 2024, with projected growth to USD 6.76 billion by 2033 at a 32.8% CAGR. Relative to your global market value of USD 1.61 billion in 2024, that implies a directional U.S. share of about 32.5%. I'm treating that as a directional comparison because the country figure is for the adjacent AI-in-medical-imaging category rather than this exact market label.

U.S. growth trends are being supported by a rising number of FDA-cleared imaging AI tools, broader enterprise adoption in radiology departments, and stronger demand for workflow efficiency and earlier diagnosis. Policy is also shaping the market. FDA clearance pathways remain central to commercialization, and federal health IT policy continues to push interoperability and digital workflow modernization. At the same time, CMS burden-reduction and AI-governance messaging are helping create a more structured environment for clinical AI deployment rather than leaving adoption to isolated pilot programs.

Japan

For Japan, public apples-to-apples sizing for this exact niche is limited, so the best grounded benchmark is the broader Japan AI in healthcare market, which reached USD 1.42 billion in 2024 in one recent market summary, with software expected to dominate and diagnostics among the major growth areas. Because that figure is broader than imaging diagnostics alone, I'm using it as a directional indicator rather than a direct like-for-like country total.

Japan's growth trend is supported by an aging population, growing imaging demand, and strong policy backing for medical digitization. The Digital Agency says Japan's Medical DX Roadmap aims to introduce a standardized electronic medical record at almost all medical institutions by 2030, a move that should improve interoperability and make AI-based imaging workflows easier to deploy at scale. That policy backdrop is especially favorable for imaging AI because standardized digital records and connected clinical systems reduce integration friction for software-led diagnostics.

Purchase This Exclusive Report: https://www.datamintelligence.com/buy-now-page?report=ai-powered-imaging-diagnostics-market?kailas

Company Profiles
Koninklijke Philips N.V.

Philips remains one of the most important companies in this market because it combines imaging hardware, clinical software, and AI-enabled workflow tools. Philips' 2025 annual reporting shows EUR 18.0 billion in sales for 2025. In imaging AI, Philips is actively positioning around platform-based diagnostics, AI-enabled radiology workflow orchestration, predictive MRI planning, and new CT systems for acute and high-demand settings. That breadth gives Philips an advantage where buyers want integrated imaging ecosystems instead of stand-alone algorithms.

Tempus AI, Inc.

Tempus is a major AI diagnostics and precision-medicine company that is increasingly active in imaging. Tempus reported USD 1.25 billion in revenue for full-year 2025, with fourth-quarter revenue of USD 367.2 million, according to its February 24, 2026 earnings release. Tempus' official radiology pages position the company around AI-enabled image analysis, workflow improvement, and tighter integration of imaging with broader clinical data. That makes Tempus especially relevant where imaging diagnostics is converging with multimodal clinical decision support.

Qure.ai Technologies Private Limited

Qure.ai is one of the most visible specialist players in imaging AI, especially in chest X-ray and CT use cases. Its February 2026 announcement said the company had reached 26 FDA-cleared indications across 9 products and more than 65 CE-certified indications, following clearance for qXR-Detect. Qure.ai's focus on high-volume imaging pathways such as chest radiography gives it strong relevance in triage-heavy and emergency-care settings, where speed and scale matter most.

Analyst View

The AI-powered imaging diagnostics market is moving from point-solution adoption toward broader clinical workflow integration. The strongest revenue pools currently appear to be in software and radiology, where imaging volume, workflow pressure, and return on investment are most visible. The United States remains the clearest large-scale commercial market due to regulatory activity and enterprise uptake, while Japan looks increasingly attractive because national Medical DX policy is improving the digital foundation required for AI deployment. Vendors that can combine clinical accuracy, workflow integration, and scalable regulatory execution are likely to capture the greatest share of growth as the market advances toward USD 9.73 billion by 2033.

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.